#United States #New York #Class Action #Levi & Korsinsky #Neumora Therapeutics

Class Action Lawsuit Filed Against Neumora Therapeutics, Inc.

On March 4, 2025, Levi & Korsinsky, LLP announced the filing of a class action lawsuit concerning Neumora Therapeutics, Inc. (NASDAQ: NMRA). This action aims to seek recovery for investors who may have suffered loss due to alleged securities fraud, and it encompasses all individuals or entities who purchased shares of Neumora’s common stock since September 15, 2023.

Understanding the Class Action

The class action lawsuit signifies a collective effort to hold the company accountable for actions perceived as misleading or harmful to investors. The complaint outlines several accusations against Neumora, which focus on the company's potentially deceptive practices surrounding its Phase Three clinical trial of Navacaprant, the firm’s lead therapeutic agent for treating Major Depressive Disorder (MDD).

Allegations of Misconduct

The crux of the allegations includes claims that:
1. In an attempt to validate its clinical trials, Neumora modified BlackThorn's original Phase Two trial criteria, expanding the patient inclusion to encompass moderate to severe MDD sufferers.
2. To further bolster trial outcomes, an additional prespecified analysis was introduced, specifically targeting this patient demographic.
3. The data from the Phase Two trials were inadequately populated, particularly regarding sample size and gender distribution, raising questions about the predictability of the study's outcomes.

Together, these claims suggest that the company may have intentionally obscured significant information, leading investors to base decisions on potentially misleading facts.

Your Rights as an Investor

If you have suffered from losses due to your investments in Neumora Therapeutics, now is the time to act. You are entitled to participate in the lawsuit, and the deadline to request the court to appoint you as a lead plaintiff is April 7, 2025. However, it's worth noting that participating in the class action does not necessitate holding the lead plaintiff position; you can still benefit from any recovery offered to the class.

No Risk to Participants

For individuals who qualify as class members, engaging in this lawsuit carries no financial obligation. You may receive compensation without incurring any personal costs or fees. This setup aims to ensure that every impacted investor has the opportunity to seek justice and recompense through this class action.

About Levi & Korsinsky, LLP

With over two decades of experience, Levi & Korsinsky has a proven track record of advocating for shareholder rights. The firm has successfully recovered millions for its clients and is recognized in the top echelon of securities litigation in the United States. Their team of over 70 skilled professionals specializes in navigating the complexities of securities law, making them a formidable advocate in the pursuit of justice.

Next Steps

Investors affected by this situation and interested in joining the lawsuit can reach out to Levi & Korsinsky for additional information and assistance. They can be contacted directly via email at email protected] or through their dedicated phone line at (212) 363-7500. For updates or specific inquiries, you can also visit their official website: [www.zlk.com.

Conclusion

In summary, the filing of this class action lawsuit against Neumora Therapeutics offers a ray of hope for investors who feel wronged by the company's practices. If you are part of the affected group, it is crucial to act promptly to secure your right to compensation and to help ensure transparency and accountability within the healthcare sector.